Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Gains Pole Position In Private-Label Allegra Race

This article was originally published in The Tan Sheet

Executive Summary

Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug

You may also be interested in...



In Brief

Dr. Reddy’s launches Allegra-D equivalent

In Brief

Dr. Reddy’s launches Allegra-D equivalent

Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance

Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel